诺思格涨2.05%，成交额1.46亿元，主力资金净流入394.35万元

Core Insights - Norscare's stock price increased by 2.05% on September 10, reaching 59.86 CNY per share, with a trading volume of 146 million CNY and a turnover rate of 4.35%, resulting in a total market capitalization of 5.781 billion CNY [1] Financial Performance - For the first half of 2025, Norscare achieved operating revenue of 380 million CNY, representing a year-on-year growth of 0.18%, and a net profit attributable to shareholders of 61.116 million CNY, up by 4.45% [2] - Since its A-share listing, Norscare has distributed a total of 49.4969 million CNY in dividends [3] Shareholder and Market Activity - As of June 30, 2025, Norscare had 10,400 shareholders, an increase of 2.06% from the previous period, with an average of 5,486 circulating shares per shareholder, a decrease of 1.97% [2] - Major shareholders include Hong Kong Central Clearing Limited, which is the seventh largest shareholder with 828,900 shares, and two new entrants in the top ten shareholders: Zhonggeng Value Dynamic Flexible Allocation Mixed Fund and Zhonggeng Value Leading Mixed Fund [3] Business Overview - Norscare, established on August 22, 2008, and listed on August 2, 2022, is based in Haidian District, Beijing, and specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [1] - The revenue composition of Norscare's main business includes: 43.01% from clinical trial operation services, 27.52% from clinical trial site management services, 13.53% from data management and statistical analysis services, 8.54% from biological sample testing services, 4.33% from clinical pharmacology services, and 3.08% from clinical trial consulting services [1]